Member Info for inanaco

for those that sold me there shares ... thank you

PS you also don't qualify for subscription shares ...

sorry

trust the BOD ....... they seem to know what they are doing .

ISA account holders ... take note ... you have a platform, thus you will be buy through that route

if you are using a platform and not share certificates ....... then the paper work goes to the platform operator

actually i see what you mean ........... sorry .... i would suggest that it is from a current collaboration, but i cannot be 100% sure WTP

its in that RNS WTP ..........

that is why i said the RNS has covered everything that folks had been complaining about ...

moditope market is probably 4 to 5 times greater than the check points .. like keytruda ...

simple reason we can hit far more cancers than Pd-1 can and i suspect at a far higher efficacy

efficacy = profit

that is a very serious balance sheet ...

well i will be filling up my ISA again ... and should get to a million shares ......... with cash going DIRECT to Scancell

Purfic

you are only looking at one side of the balance sheet Dick

if you look at the other side

readout from Moditope and Keytruda with immunobody

reminder

Advanced commercial discussions are currently underway with a global biotech with initial commercial collaboration potentially to be in the form of granting a partner an option to a future licence.

so every bit of Info that some wanted is in there ...... indeed a clear link to a deal forming on Avidmab ...

Interesting BioNtech TCR is not being allocated any funds ... is that near completion ?

really the only question to ask at the general meeting ............ BioNtech ?

The Company has entered into three non-exclusive research agreements with leading antibody technology companies in Europe, the USA and China to evaluate the Company's anti-TaG mAbs including those enhanced with the AvidiMab™ technology. TaGs can be targeted by several other tumour cell killing approaches, including antibody drug conjugates (ADC), redirected T-cells, and also adoptive cell therapies such as chimeric antigen receptor (CAR) T cells. Under the terms of the collaboration and research agreements, Scancell and its partners will evaluate the potential of the anti-TaG mAbs, in these various formats. The Company expects these collaboration and research agreements could transition into potential partnerships. Advanced commercial discussions are currently underway with a global biotech with initial commercial collaboration potentially to be in the form of granting a partner an option to a future licence.

As reported in June 2020, formal regulatory-compliant toxicity studies have now been completed, with no evidence of any local or systemic toxicities being reported. In addition to the Scientific Advice meeting held with the Paul-Ehrlich-Institut regulatory authority in 2019, a further successful meeting was held with the UK Medicines and Healthcare products Regulatory Agency in February 2020. The Company continues to progress the necessary processes and documentation required for regulatory submission to start the planned clinical study in the UK in the first half of 2021, with clinical trial application targeted for the fourth quarter of 2020 (subject to completion of the Capital Raise). Based on these current timeline expectations, interim data is expected in the second half of 2021 which is likely to include safety data and potentially early efficacy indicators. A more extensive trial result read out is expected around the end of 2022.

Initial research is underway and Scancell is actively seeking development partners and additional funding (including non-dilutive funding from governments and global institutions) to support the rapid development of this vaccine. Subject to such funding being secured, Scancell anticipates initiating a Phase 1 clinical trial known as COVIDITY in the first quarter of 2021.

As reported in April 2019, the Company has received the necessary regulatory and ethical approvals to initiate the UK arm of the SCIB1 clinical trial and as announced in February 2020, the IND application to the FDA for SCIB1 was also approved. Following regulatory approval, patient screening was initiated in the UK, with Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham as the Chief Investigator for the global study; however the impact of COVID-19 means other sites will be initiated later in the second half of 2020. Subject to completion of the Capital Raise, site initiation is expected to be focussed in the UK initially with commencement of patient enrolment later in the second half of 2020, with interim clinical data expected in the first half of 2021.

they have been tested .. hence breathing non covid air out ... LOL

tf Ivy called me a racists ... you maybe a good painter i do not know ... ? but put the gloss away ..

Tf
it seems ever since you have got a bee in your bonnet over Covid, masks, heathrow being open etc. you have constantly attacked any one with a different view point, and given Poor Boris hell .. inc name calling ... Yet as evidenced now .. the Government followed Sage advice ... and yet nobody stopped you posting or tried to run you off the BB ... you seem to be playing both sides of the fence ... bit like corbyn over brexit ... however stand in the middle of a motorway .. go left or right you can be run over ... that is the risk ... the devil you know well ... or the devil you don't either way .... lozan still calls you tarquin ... or what ever it is

tf he called me a racist ... do i assume you find that acceptable .. ? is that what you call a different view point ?

yes but unfortunately he does not have the life experience or the technical ability to handle me ... hence his childish outbursts seen it all before

Aimbig ............ got it ...

many try to get back in by registering .. but they leave a signature in the way they post .. which we spot .